IVIg in Dermatology - EADV

More documents

Recommendations

Info

Pre-tibial myxoedema • Two contradictory reports • Patient numbers: 7 patients (1), 1patient (2) • Dosage of IVIg: – 2g/kg bw / cycle (7 – 15 cycles every 3 weeks) (1) – 2g/kg bw / cycle (6 monthly cycles) (2) • Treatment protocol: • Results • 7/7 patients with clinical improvement of skin lesions, ophthalmopathy, reduction in auto-antibody levels • 1/1 patient without clinical response but reduction inanti-TSH receptor antibody titers • Literatur – Antonelli A et al, Thyroid 1994, 4: 399 – 408 – Terheyden P et al, Clin Exp Dermatol 2003, 28: 224 - 226 EADV 2007
IVIG in vasculitis and connective tissue disorders (Fierlbeck 02/07) Disorder Large-vessel vasculitis Behcet`s disease Medium-vessel vasculitis Kawasaki disease Polyarteritis nodosa Small-vessel vasculitis ANCA-associated vasculitis Leucocytoclastic vasculitis SLE Lupus nephritis Cutaneous lupus Antiphospholipid syndrome Obstetric use Livedoid vasculitis Pyoderma gangraenosum Level of Evidence IV I IV I IV II III II III IV Grade of recommendation D A D B D B D C D D
Page 1: IVIg in Dermatology Update EADV 200
Page 10 and 11: Registered indications for IVIg Sub
Page 12 and 13: Dermatomyositis • Incidence 1:100
Page 14 and 15: Involvement of other organs • Gen
Page 16: Cytokines •TNF alpha •IL-1 •I
Page 25 and 26: Indications for IVIG in autoimmune
Page 27 and 28: Pemphigus • Pemphigus vulgaris ap
Page 29 and 30: Pemphigoid • Bullous Pemphigoid -
Page 31 and 32: Epidermolysis bullosa acquisita •
Page 33 and 34: Study design: randomised, prospecti
Page 35 and 36: Atopic eczema • Study design: Cas
Page 37: Pyoderma gangraenosum • Study des
Page 46: Der Einsatz von Immunglobulinen bei

IVIg in Dermatology - EADV

Create successful ePaper yourself

Delete template?

Save as template?